Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive/HER2-positive breast cancer - The TOUCH trial

被引：0
|
作者：
Biganzoli, Laura
Brain, Etienne
Malorni, Luca
Gombos, Andrea
Hasler-Strub, Ursula
Zamagni, Claudio
Chakiba, Camille
Roschitzki-Voser, Heidi
Regan, Meredith M.
机构：
[1] Int Breast Canc Study Grp, Bern, Switzerland
[2] TOUCH Investigators, Bern, Switzerland
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT-28-02
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.
    Villagrasa, Patricia
    Gonzalez, Xavier
    Oliveira, Mafalda
    Vazquez, Josep
    De La Pena, Lorena
    Llobet-Canela, Marta
    Prat, Aleix
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer
    Mayer, Erica L.
    Baurain, Jean-Francois
    Sparano, Joseph
    Strauss, Lewis
    Campone, Mario
    Fumoleau, Pierre
    Rugo, Hope
    Awada, Ahmad
    Sy, Oumar
    Llombart-Cussac, Antonio
    CLINICAL CANCER RESEARCH, 2011, 17 (21) : 6897 - 6904
  • [33] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [34] Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
    Liang Huang
    Da Pang
    Hongjian Yang
    Wei Li
    Shusen Wang
    Shude Cui
    Ning Liao
    Yongsheng Wang
    Chuan Wang
    Yuan-Ching Chang
    Hwei-Chung Wang
    Seok Yun Kang
    Jae Hong Seo
    Kunwei Shen
    Suphawat Laohawiriyakamol
    Zefei Jiang
    Haiyan Wang
    François Lamour
    Grace Song
    Michelle Curran
    Chunzhe Duan
    Sanne Lysbet de Haas
    Eleonora Restuccia
    Zhimin Shao
    Nature Communications, 15
  • [35] De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab in HER2-positive early breast cancer (HELEN-006):a randomized,phase 3 trial
    Liu, Zhenzhen
    Chen, Xiuchun
    Qiao, Jianghua
    Jiao Dechuang
    Wang, Chengzheng
    Sun, Xianfu
    Lu, Zhenduo
    Li, Lianfang
    Zhang, Chongjian
    Yan, Min
    Wei, Ya
    Bo, Chen
    Feng, Yueqing
    Deng, Miao
    Ma, Mingde
    CANCER RESEARCH, 2024, 84 (09)
  • [36] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
    Yardley, Denise A.
    Daniel, Davey
    Stipanov, Michael
    Drosick, D. Randolph
    Mainwaring, Mark
    Peyton, James
    Shastry, Mythili
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
  • [37] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
  • [38] Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor-or Progesterone Receptor-Positive Breast Cancer
    Forero-Torres, Andres
    Saleh, Mansoor N.
    Galleshaw, Janice A.
    Jones, Cheryl F.
    Shah, Jatin J.
    Percent, Ivor J.
    Nabell, Lisle M.
    Carpenter, John T.
    Falkson, Carla I.
    Krontiras, Helen
    Urist, Marshall M.
    Bland, Kirby I.
    De Los Santos, Jennifer F.
    Meredith, Ruby F.
    Caterinicchia, Valerie
    Bernreuter, Wanda K.
    O'Malley, Janis P.
    Li, Yufeng
    LoBuglio, Albert F.
    CLINICAL BREAST CANCER, 2010, 10 (04) : 275 - 280
  • [39] Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
    Loi, Sherene
    Salgado, Roberto
    Curigliano, Giuseppe
    Romero Diaz, Roberto Ivan
    Delaloge, Suzette
    Rojas Garcia, Carlos Ignacio
    Kok, Marleen
    Saura, Cristina
    Harbeck, Nadia
    Mittendorf, Elizabeth A.
    Yardley, Denise A.
    Suarez Zaizar, Alberto
    Caminos, Facundo Rufino
    Ungureanu, Andrei
    Reinoso-Toledo, Joaquin G.
    Guarneri, Valentina
    Egle, Daniel
    Ades, Felipe
    Pacius, Misena
    Chhibber, Aparna
    Chandra, Rajalakshmi
    Nathani, Raheel
    Spires, Thomas
    Wu, Jenny Qun
    Pusztai, Lajos
    Mcarthur, Heather
    NATURE MEDICINE, 2025, 31 (02) : 433 - 441
  • [40] Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer
    Loesch, David
    Asmar, Lina
    McIntyre, Kristi
    Doane, Lisa
    Monticelli, Michael
    Paul, Devchand
    Vukelja, Svetislava
    Orlando, Mauro
    Vaughn, LaTrice G.
    Zhan, Feng
    Boehm, Kristi A.
    O'Shaughnessy, Joyce A.
    CLINICAL BREAST CANCER, 2008, 8 (02) : 178 - 186
12345